ONCOLOGY & DOSIMETRY
Personalized Radionuclide Therapy with Hybrid Dosimetry™ & Olinda / EXM®2.0
Each patient responds differently to treatment, and serial radionuclide imaging provides patient specific information about the individual nuclide kinetics in tumors and normal organs after an administered dose.
Hybrid Dosimetry™ provides a fast and efficient way to generate kinetic data for selected organs. The residence times calculated using this data are seamlessly passed to OLINDA/EXM® 2.0, which generates absorbed dose tables using the MIRD methodology.
Absolute quantification for PET and SPECT brings about a revolution in the assessment of response to therapy over multiple time points, in addition to making visual comparison easier through the use of an absolute scale.
- MIRD s-factor dose calculations
- More than 400 additional radionuclides added
- Compute the residence time, and subsequent dose for each organ
- ICRP 89 “NURBs” Phantoms can now be selected for Human Dosimetry